Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy. (11th October 2019)

• Record Type: Journal Article
• Authors: Marks, Michael; Bell, Lucy C K; Jones, Imogen; Rampling, Tommy; Kranzer, Katharina; Morris-Jones, Stephen; Logan, Sarah; Pollara, Gabriele
• Is Part Of: Clinical infectious diseases. Volume 71:Number 1(2020)
• Page Start: 207
• Page End: 210
• Publication Date: 2019-10-11
• Subjects: OVIVA -- OPAT -- IV antibiotics; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz991
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5–37) and GBP 1234 (569–2594) per patient.